A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
| Autor: | ten Cate, B.1,2, Bremer, E.3, de Bruyn, M.2, Bijma, T.2, Samplonius, D.2, Schwemmlein, M.4, Huls, G.5, Fey, G.4, Helfrich, W.2 w.helfrich@med.umcg.nl |
|---|---|
| Zdroj: | Leukemia (08876924). Aug2009, Vol. 23 Issue 8, p1389-1397. 9p. 1 Chart, 5 Graphs. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|